rifametane

Known as: 3-(((1-(diethylamino)ethylidene)hydrazono)methyl)rifamycin, 3-((1-diethylaminoethylidene)azinomethyl)rifamycin SV, 3-azinomethyl-rifamycin 
A semisynthetic derivative of rifamycin with a longer biological half-life than rifampicin.
National Institutes of Health

Topic mentions per year

Topic mentions per year

1988-2000
0119882000

Papers overview

Semantic Scholar uses AI to extract papers important to this topic.
2000
2000
Single and repeated dose experiments in mice, rats, dogs and monkeys are reported in this study to assess the pharmacokinetics… (More)
Is this relevant?
1999
1999
An open randomized cross-over study was conducted in 8 healthy male volunteers to study the pharmacokinetic pattern and the… (More)
Is this relevant?
1998
1998
The pharmacokinetics and tolerance of a single oral dose (150 mg) of a new 3-azinomethyl rifamycin (SPA-S-565, USAN rifametane… (More)
Is this relevant?
1996
1996
The in-vitro activity of a 3-azinomethyl-rifamycin (SPA-S-565) against Chlamydia trachomatis was compared to that of rifampicin… (More)
Is this relevant?
1988
1988
The new 3-azinomethyl-rifamycin, SPA-S-565, was shown to exert an effective antibacterial activity in vitro comparable to that of… (More)
Is this relevant?